ExpreS2ion Biotech Holding AB
STO:EXPRS2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Yellow Pages Ltd
TSX:Y
|
CA |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (1.2), the stock would be worth kr0.86 (63% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3.2 | kr2.35 |
0%
|
| 3-Year Average | 1.2 | kr0.86 |
-63%
|
| 5-Year Average | 505.6 | kr366.59 |
+15 499%
|
| Industry Average | 7.9 | kr5.72 |
+143%
|
| Country Average | 2.1 | kr1.54 |
-34%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
kr-23.4m
|
/ |
Jan 2026
kr12.2m
|
= |
|
|
kr-23.4m
|
/ |
Dec 2026
kr10.1m
|
= |
|
|
kr-23.4m
|
/ |
Dec 2027
kr258.6m
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| SE |
E
|
ExpreS2ion Biotech Holding AB
STO:EXPRS2
|
86.3m SEK | 3.2 | -0.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 691 034.4 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.6B USD | 6.7 | 85.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.9B USD | 6.2 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
165.4B USD | 6 | 19.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 092.7 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.9B USD | 8.6 | 28.1 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79B USD | 4 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42B EUR | 10.8 | 38 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.1B AUD | 3.4 | 30.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 19.6 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 2.1 |
| 70th Percentile | 5.1 |
| Max | 15 188 |
Other Multiples
ExpreS2ion Biotech Holding AB
Glance View
Expres2ion Biotech Holding AB engages in the development of a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer. The company is headquartered in Helsingborg, Skane and currently employs 29 full-time employees. The company went IPO on 2016-07-29. The firm specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The firm's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. The company also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.
